Page 110 - Read Online

Gómez-Mendoza et al. Metab Target Organ Damage. 2025;5:24 https://dx.doi.org/10.20517/mtod.2024.108 Page 7 of 8

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2025.

REFERENCES
1. Vos MB, Abrams SH, Barlow SE, et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty
liver disease in children: recommendations from the expert committee on NAFLD (ECON) and the North American Society of
Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr. 2017;64:319-34. DOI PubMed
PMC
2. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease
(NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335-47. DOI PubMed PMC
3. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from
the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328-57. DOI PubMed
4. Kim GA, Moon JH, Kim W. Critical appraisal of metabolic dysfunction-associated steatotic liver disease: implication of Janus-faced
modernity. Clin Mol Hepatol. 2023;29:831-43. DOI PubMed PMC
5. Rinella ME, Lazarus JV, Ratziu V, et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new
fatty liver disease nomenclature. Ann Hepatol. 2024;29:101133. DOI PubMed
6. Dongiovanni P, Paolini E, Corsini A, Sirtori CR, Ruscica M. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty
liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches. Eur J Clin Invest. 2021;51:e13519. DOI
PubMed
7. Godoy-Matos AF, Silva Júnior WS, Valerio CM. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetol
Metab Syndr. 2020;12:60. DOI PubMed PMC
8. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European
Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic
dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492-542. DOI PubMed
9. Roeb E. Excess body weight and metabolic (Dysfunction)-associated fatty liver disease (MAFLD). Visc Med. 2021;37:273-80. DOI
PubMed PMC
10. Wong VW, Ekstedt M, Wong GL, Hagström H. Changing epidemiology, global trends and implications for outcomes of NAFLD. J
Hepatol. 2023;79:842-52. DOI PubMed
11. Lazarus JV, Mark HE, Allen AM, et al; Healthy Livers, Healthy Lives Collaborators. A global research priority agenda to advance
public health responses to fatty liver disease. J Hepatol. 2023;79:618-34. DOI PubMed
12. Yu EL, Schwimmer JB. Epidemiology of pediatric nonalcoholic fatty liver disease. Clin Liver Dis. 2021;17:196-9. DOI PubMed
PMC
13. Hartmann P, Zhang X, Loomba R, Schnabl B. Global and national prevalence of nonalcoholic fatty liver disease in adolescents: an
analysis of the global burden of disease study 2019. Hepatology. 2023;78:1168-81. DOI PubMed PMC
14. Han MAT, Yu Q, Tafesh Z, Pyrsopoulos N. Diversity in NAFLD: a review of manifestations of nonalcoholic fatty liver disease in
different ethnicities globally. J Clin Transl Hepatol. 2021;9:71-80. DOI PubMed PMC
15. Younossi ZM, Loomba R, Anstee QM, et al. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis,
and associated fibrosis. Hepatology. 2018;68:349-60. DOI PubMed PMC
16. López-velázquez JA, Silva-vidal KV, Ponciano-rodríguez G, et al. The prevalence of nonalcoholic fatty liver disease in the Americas.
Ann Hepatol. 2014;13:166-78. DOI
17. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-
analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84. DOI PubMed
18. Rojas YAO, Cuellar CLV, Barrón KMA, Arab JP, Miranda AL. Non-alcoholic fatty liver disease prevalence in Latin America: a
systematic review and meta-analysis. Ann Hepatol. 2022;27:100706. DOI PubMed
19. Chinchilla-López P, Ramírez-Pérez O, Cruz-Ramón V, et al. More evidence for the genetic susceptibility of mexican population to
nonalcoholic fatty liver disease through PNPLA3. Ann Hepatol. 2018;17:250-5. DOI PubMed
20. Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty